XBiotech (XBiotech) EBIT : $-41.22 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is XBiotech EBIT?

XBiotech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-10.85 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-41.22 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. XBiotech's annualized ROC % for the quarter that ended in Mar. 2024 was -144.44%. XBiotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -174.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. XBiotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -59.68%.

XBiotech EBIT Historical Data

The historical data trend for XBiotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech EBIT Chart

XBiotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-31.23

-18.28

-25.08

-34.49

-37.51

XBiotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-7.15	-13.26	-8.52	-8.59	-10.85

Competitive Comparison of XBiotech's EBIT

For the Biotechnology subindustry, XBiotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XBiotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XBiotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where XBiotech's EV-to-EBIT falls into.

XBiotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.22 Mil.

XBiotech (NAS:XBIT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

XBiotech's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-43.412 * ( 1 - -0.25% )	/	( (25.459	+	34.802)	/ 2 )
=	-43.52053	/	30.1305
=	-144.44 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	226.615	-	5.538	-	( 200.023	-	max(0, 6.1	-	201.718	+	200.023	))
=	25.459

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	227.858	-	6.884	-	( 201.039	-	max(0, 16.884	-	203.056	+	201.039	))
=	34.802

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

XBiotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-43.412	/	( ( (24.897 + max(-5.34, 0))	+	(24.802 + max(-5.812, 0)) )	/	2 )
=	-43.412	/	( ( 24.897	+	24.802 )	/	2 )
=	-43.412	/	24.8495
=	-174.70 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.75999999999999)	-	(5.538	+	0	+	0.562)
=	-5.34

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.072)	-	(6.884	+	0	+	0)
=	-5.812

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

XBiotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-41.218	/	69.068
	=	-59.68 %

XBiotech EBIT Related Terms

Thank you for viewing the detailed overview of XBiotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

XBiotech (XBiotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

4XB:Germany 4XB:Germany

Address

5217 Winnebago Lane, Austin, TX, USA, 78744

Website

http://www.xbiotech.com

XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

Executives

Angela Hu	officer: Principle Financial Officer	5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard	director, 10 percent owner	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a.	10 percent owner	MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie	director, 10 percent owner	735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy	officer: VP of R&D	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han	officer: VP of Fin & HR, Secretary	8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut	10 percent owner	CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby	director	109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes	10 percent owner	RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam	director	56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin	director	77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman	officer: Sr.VP Corp. Strategy & Finance	8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson	officer: VP of Commercial Development	8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury	officer: VP of Business Development	8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough	officer: VP Clinical Operations	115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703